Scott Gottlieb, M.D.

Scott Gottlieb is an American physician who served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping health care delivery, and expanding consumer choice and safety. He is a resident fellow at the American Enterprise Institute, a member of the board of directors of drug maker Pfizer, a member of the board of directors of the biotech company Illumina, a contributor to the cable financial news network CNBC, and a partner at the venture capital firm New Enterprise Associates.

Dr. Gottlieb's book, Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic published to The New York Times Best Seller list in September 2021. He is also widely published in leading medical journals and periodicals and has held editorial positions on the British Medical Journal and the Journal of the American Medical Association. Dr. Gottlieb is a regular contributor to CNBC and CBS's "Face the Nation." In 2018 and again in 2019, Dr. Gottlieb was recognized by Fortune Magazine as one of "The World's 50 Greatest Leaders" and by Time Magazine as one of the “50 People Transforming Healthcare.”

Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines. Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The FDA implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real-world evidence. They promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises.

• Download Full Bio >

• Source

  Dr. Scott Gottlieb on promising new cancer drug data: ‘The future is here’

  (CNBC) – Dr. Scott Gottlieb joins CNBC’s ‘Squawk Box’ to discuss the top drug trial data coming out of the American Society of Clinical Oncology conference in Chicago.

• Source

  Dr. Scott Gottlieb believes omicron BA.2 subvariant unlikely to cause ‘national wave’ in U.S.

  (CNBC) – Dr. Scott Gottlieb believes the U.S. this spring will avoid a “national wave” of infection related to the more contagious.

• Source

  Americans Are Still Living With a 2020 Attitude Toward COVID-19 Risk. It’s Time for That to Change

  (TIME) – We’ve gradually found a way to coexist with this virus. Now we need a glide path to what normal becomes and a new math to guide how we adapt to COVID-19 even if we never fully defeat it.

• Source

  America needs a confirmed leader at FDA — now

  (The Hill) – The FDA is vital to their solutions; more than a year into a new administration, it is long past time to have confirmed leadership at the FDA.

• Source

  Gottlieb predicts “broad immunity” among children as more get COVID-19 vaccine

  (CBD) – Gottlieb said the U.S. is close to the end of the “pandemic phase” of COVID-19 and is entering a more “endemic” phase.

• Source

  Why the U.S. pandemic playbook was no match for COVID

  (NPR) – The country urgently needs to upgrade its pandemic response capabilities to prevent future infectious calamities, argues former Food and Drug Administration Commissioner Scott Gottlieb.

• Source

  How to avert and prep for the next pandemic: Q&A with Dr. Scott Gottlieb

  (CNN) – “I don’t think pandemics need to happen. I think emerging viruses will happen, but I don’t think that they need to turn into pandemics,” Gottlieb told CNN Chief Medical Correspondent Dr. Sanjay Gupta in his podcast, Chasing Life.

• Source

  Intelligence agencies can help stop future pandemics. Here’s how.

  (Washington Post) – The United States could have been better prepared for the coronavirus — and it could be better prepared for the next deadly pandemic.

• Source

  ‘Uncontrolled Spread’ Review

  (WSJ) – A former Food and Drug Administration commissioner surveys what went wrong with America’s response to the Covid pandemic.

• Source

  Former FDA commissioner: ‘We remain almost equally vulnerable to threat from the next pandemic’

  (Washington Post) – Scott Gottlieb, 49, is the author of “Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic.”

• Source

  The Need for a US National Clinical Trial Infrastructure in a Public Health Crisis

  (JAMA) – In the absence of conclusive information, findings from speculative studies, observational data, and anecdotes were able to fill the ensuing information vacuum.

• Source

  How a Coronavirus Expert Shook Up CBS’ ‘Face The Nation’

  (Variety) – “I look forward to a day when I can talk about anything other than the pandemic.”

• Source

  Gottlieb calls for “broader view” in assessment of coronavirus origin

  (CBS) – Dr. Scott Gottlieb said officials need to take a “broader view” when assessing the origins of the coronavirus, and defended Dr. Anthony Fauci from criticism over his early handling of the pandemic.

• Source

  Beat Tomorrow’s Pandemic Today

  (WSJ) – This is a good time to start building up capacity to fight the next novel pathogen.

• Source

  Moderation on Masks Might Make More Get a Shot

  (WSJ) – Many unvaccinated Americans aren’t ‘antivaxxers,’ but need incentive and information.

• Patent Busting Won’t Help Vaccinate the World Faster

  (WSJ) – The solution is to ease restrictions on exporting shots and build more production capacity.

• Source

  CDC can consider lifting indoor Covid mask mandates now, former FDA chief says

  (CNBC) – Gottlieb explained that the overall outlook for vaccinations in the U.S. “looks very good.”

• Source

  Transcript: Scott Gottlieb discusses coronavirus on “Face the Nation,” May 2, 2021

  (CBS) – I’m hopeful that the FDA is going to authorize the Pfizer vaccine, the company I’m on the board of as applied for permission to start giving its vaccine to 12 to 15 year olds.

• Source

  Want to Go Back to the Office? Don’t Wait on the CDC

  (WSJ) – Businesses should band together and formulate flexible guidance suitable to their own industries.

• Source

  Time to End Outdoor Mask Edicts

  (WSJ) – The CDC is moving too slowly in updating its advice to comport with the scientific evidence.

• Source

  Drug Safety Is FDA’s Job, Not CDC’s

  (WSJ) – Clear lines of authority would make it easier to resolve the Johnson & Johnson complications.

• Source

  Covid Arsenal Needs Pills as Well as Shots

  (WSJ) – A drug that could prevent severe symptoms could help those who can’t or won’t get vaccinated.

• Source

  How Dr. Scott Gottlieb protects his young kids on playdates before they can get Covid shots

  (CNBC) – A person who received a Covid shot should still wear a mask around an at-risk individual who hasn’t been vaccinated.

• Source

  With 2M Shots In Arms, Looking To Winter Boosters

  (CT News) – Despite worries that the country was heading for a fourth wave, Gottlieb said he believed the nation had crossed an “inflection point” and he expected spikes to be more isolated than in the past.

• Source

  How to Make Spring the Last Lost Semester

  (WSJ) – With Covid precautions and eventual vaccines for children, classrooms can reopen in time for the fall.

• Source

  Where’s the Science Behind CDC’s 6-Foot Social-Distance Decree?

  (WSJ) – The new limit for schools is 3 feet. But the public is in the dark about the basis of these recommendations.

• Source

  Quarantining cities isn’t needed. But a fast, coordinated response to covid-19 is essential.

  By WWSG exclusive speakers Scott Gottlieb & Caitlin Rivers Scott Gottlieb is a former commissioner of the Food and Drug Administration. Caitlin M. Rivers, an epidemiologist, is a senior scholar at the Johns Hopkins Center for Health Security. Dramatic measures have been taken over the past week to fight the coronavirus epidemic in the United […]

• Source

  Send Out the Search Party for New Covid Strains

  (WSJ) – Variants of the virus can be stopped if uncovered early—but that will require more genetic sequencing.

• Source

  Transcript: Scott Gottlieb discusses coronavirus on “Face the Nation,” February 21, 2021

  (CBS) – Transcript: Scott Gottlieb discusses coronavirus on “Face the Nation,” February 21, 2021

• Source

  You Can Trust the FDA’s Vaccine Process

  (Wall Street Journal) – The agency can roll out a Covid shot safely, quickly and without bowing to political pressure.

• Source

  How ‘Emergency Use’ Can Help Roll Out a Covid Vaccine

  (The Wall Street Journal) – The FDA can approve a promising candidate for those most at risk while continuing to collect data.

• Source

  Dr. Gottlieb: Vaccine For General Population Unlikely By This Year

  (MSNBC) – Former FDA Commissioner Dr. Scott Gottlieb weighs in on the suspension of a COVID-19 vaccine trial, the likelihood of a vaccine for the general public this year and what he expects from the coming flu season. 

• Source

  Sweden Shouldn’t Be America’s Pandemic Model

  (The Wall Street Journal) – The Swedes aren’t close to reaching herd immunity. We need to continue to contain the virus spread.

• Source

  Betting on Better Drug Trials to Beat Covid-19

  (The Wall Street Journal) – Studies are competing for too few patients. It’s time to direct resources toward the most promising therapies.

• Source

  Want Schools to Open? Get Serious About Outbreaks

  (The Wall Street Journal) – The spring decision to open inessential businesses came at the expense of fall classrooms.

• Source

  Scott Gottlieb: High rate of COVID-19 spread in schools making it “very hard to open” in fall

  (Face The Nation) – The former FDA commissioner suggests that testing delays need to be resolved before widespread reopenings of America’s schools.

• Source

  Covid Shows the Need for a Diagnostic Stockpile

  (The Wall Street Journal) – Congress can meet the current surge in demand for testing and be ready for the next pandemic.

• Source

  Behind the HHS-CDC Disagreement

  (The Wall Street Journal) – An interagency feud over key data demonstrates the inadequacy of U.S. efforts to prepare for a pandemic.

• Source

  Schools Can Open Safely This Fall

  (Wall Street Journal) – Staggered schedules and other precautions would help reduce children’s low but real risk from Covid.

• Source

  Antibodies Can Be the Bridge to a Vaccine

  (The Wall Street Journal) – Drugs that mimic an immune response are in development, but it’s time to ramp up manufacturing.

• Source

  Reinvent Health Care to Beat Covid-19

  (The Wall Street Journal) – Important surgeries can continue, but doctors need to be paid more for managing outbreaks.

• Source

  Rules for Clinical Trials in a Pandemic

  (The Wall Street Journal) – A study out of Britain shows how to learn more, faster about promising coronavirus treatments.

• Source

  New Rules for Covid Summer: Be Flexible and Vigilant

  (The Wall Street Journal) – The public is divided. Authorities need to build confidence without wearing out goodwill.

• Source

  ‘We Can’t Let Our Guard Down’ On Virus, Says Dr. Gottlieb

  (MSNBC) – Former FDA commissioner Dr. Scott Gottlieb says the coronavirus epidemic is still spreading but at a slower rate.

• Source

  How Businesses Can Keep Employees Safe From Coronavirus

  (The Wall Street Journal) – Companies can deploy routine testing and tools like pooling samples to detect outbreaks.

• Source

  A Fast Coronavirus Vaccine, Without Cutting Corners

  (The Wall Street Journal) – Rigorous testing will ensure that Americans can trust the shot they take will be safe and effective.

• Source

  Scott Gottlieb warns of uptick in coronavirus infections after widespread protests

  (Face The Nation)  – Former FDA Commissioner Scott Gottlieb cautioned against the potential spread of coronavirus as thousands of people take to the streets to demonstrate.

• Source

  Here’s the Testing Strategy We Need to Safely Reopen America

  (TIME) – Everyone wants to know when we’ll be safe from COVID-19. The answer is we’re probably in for a long fight. We’ll face a persistent risk, maybe until we get a vaccine, or even after. But that risk can be managed, and reduced, if we focus on helping those at the greatest threat of getting the disease.

• Source

  Cut Through the Fog of Coronavirus War

  (The Wall Street Journal) – The Centers for Disease Control and Prevention made its first definitive statement last week describing a rare but disturbing condition in children related to Covid-19.

• Source

  Antibody Knowledge Can Be Power

  (The Wall Street Journal) – Covid-19 may be here for a long time. As work and activities begin to resume, there will continue to be risk and many new precautions.

• Source

  Gottlieb says coronavirus mitigation “didn’t work as well as we expected” in reducing cases

  (Face The Nation) – The former FDA commissioner said new coronavirus cases continue to rise in roughly 20 states.

• Source

  The Cruel Covid ‘New Normal’

  (The Wall Street Journal) – The virus continues to spread. What’s needed now: rapid antigen tests like the one for flu or strep.

• Source

  America Needs to Win the Coronavirus Vaccine Race

  (The Wall Street Journal) – The first nation to develop a vaccine for Covid-19 could have an economic advantage as well as a tremendous public-health achievement.

• Source

  How to Keep Workers Healthy on the Job

  (The Wall Street Journal) – The threat from Covid-19 won’t end when the epidemic subsides. The recent upsurge in cases in Singapore and Japan shows how easily the virus can re-emerge. It will be a constant threat until an effective vaccine is on the market. So how does America function?

• Source

  Former FDA chief grabs spotlight with coronavirus plans to ‘turn the lights back on’

  (The Washington Post) – A year after Scott Gottlieb resigned unexpectedly as Food and Drug Administration commissioner to return home to his family in Westport, Conn., he has never been in such demand — advising lawmakers, governors, members of the Trump administration and even the president himself about combating the novel coronavirus.

• Source

  The Employer Will Test You Now

  (The Wall Street Journal) – Reopening the economy will depend on companies diagnosing coronavirus cases in the workplace.

• Source

  Bet Big on Treatments for Coronavirus

  (The Wall Street Journal) – Antivirals and antibody therapies are showing promise. The FDA needs to step up its pace.

• Source

  ‘It Tortures Me That I’m Not There Helping.’ Former FDA Commissioner Scott Gottlieb on the Fight Against COVID-19

  (TIME) – Despite the fact that Gottlieb is working from home, he arguably has been in the public eye more now than at any time since he resigned from the FDA last spring.

• Source

  Scott Gottlieb becomes key voice warning Trump, GOP on coronavirus

  (The Hill) – Scott Gottlieb has seen his national profile grow amid the coronavirus outbreak as the former Food and Drug Administration commissioner becomes a leading voice from outside the administration on how to tackle the worst health epidemic the country may ever have faced.

• Source

  How Long Will the Coronavirus Lockdowns Go On?

  (The Wall Street Journal) – Soon the U.S. will be able to do 75,000 tests a day. That will make changes in strategy possible.

• Source

  Scott Gottlieb expects “shocking” scenes in New York as coronavirus spreads

  (Face the Nation) – The former FDA chief says hospitals are at risk of being overwhelmed during the crisis.

• Source

  American Hospitals Can Avoid Italy’s Fate

  (The Wall Street Journal) – Deploy telemedicine to determine who needs emergency care, waive licensing rules and more.

• Source

  The shadow coronavirus czar

  (Politico) – Scott Gottlieb left the Trump administration nearly a year ago — but from Twitter to TV, he’s become the face of truth-telling about the coronavirus pandemic.

• Source

  Quarantining cities isn’t needed. But a fast, coordinated response to covid-19 is essential.

  (The Washington Post) – Dramatic measures have been taken over the past week to fight the coronavirus epidemic in the United States. President Trump’s announcement of a ban on most flights from Europe, except for the United Kingdom, on Wednesday night came at about the same time the National Basketball Association suspended the rest of the basketball season.

• Source

  Take smart steps to slow spread of the coronavirus

  (USA Today) – Small steps like hand-washing and covering coughs can not only reduce our risks of infection but also have a big impact on the scope of an epidemic.

• Source

  Covid-19 May Have You Working At Home

  (The Wall Street Journal) – The numbers don’t tell the whole story. Nine Americans have died of Covid-19, and the Centers for Disease Control and Prevention confirms more than 100 cases in 15 states. But there are probably already several thousand Americans who have been infected. For now, the average person’s risk is low in a nation of 330 million, but that may soon change.

• Source

  Why Does the U.S. Have So Few Confirmed Coronavirus Cases?

  (The Wall Street Journal) – A mere 15 cases of the Wuhan coronavirus have been diagnosed in the U.S., according to the Centers for Disease Control and Prevention, and that number hasn’t budged in a week. But the true number of cases is unknown, because the U.S. is testing only those who recently arrived from China or have been in close contact with confirmed patients.

• Source

  Gottlieb says screening and fist bumps over handshakes will help protect against coronavirus

  (CNBC) – Coronavirus is spreading in Hong Kong, Thailand, and Singapore. Community spread is suspected in other nations. Models suggest that for every person who traveled into the U.S. infected with coronavirus, and who was successfully diagnosed and quarantined, maybe three more arrived undetected.

• Source

  Former FDA Chief Scott Gottlieb answers viewer questions on coronavirus

  (CNBC) – Dr. Scott Gottlieb, Pfizer board member and former FDA commissioner, answers viewers’ questions about the coronavirus outbreak.

• Source

  Can an inflation cap on drugs be inflationary?

  (AEI) – Members of the Senate Finance Committee have fashioned a well-meaning effort to modernize the Medicare drug benefit. Among its key features, the bill would help protect seniors from high out-of-pocket costs by limiting beneficiary cost sharing to $3,100 annually.

• Source

  Containing the Spread of the Coronavirus

  (CNBC) – Dr. Gregory Poland, professor of medicine and infectious diseases and the director of the Vaccine Research Group at Mayo Clinic, and Dr. Scott Gottlieb, Pfizer board member and former FDA Commissioner, join CNBC to discuss the spread of misinformation on the coronavirus.

• Source

  Act Now to Prevent an American Epidemic

  (Wall Street Journal) – Quarantines, flu vaccines and other steps to take before the Wuhan virus becomes widespread.

• Source

  We need to prepare for US outbreak of Wuhan coronavirus

  (CNBC) – Even though there’s a lot that we don’t know about the novel coronavirus that’s burning its ways through China, there are some critical assumptions we should make about its continued spread.

• Source

  The world is better prepared for the coronavirus threat. But we remain tragically vulnerable.

  (The Washington Post) – Health authorities’ concern about the new coronavirus in China, with cases spreading in Asia and as far as the United States, deepened Wednesday with news that the Chinese government plans to shut down transportation from Wuhan, a city of 11 million people that is considered ground zero of the pneumonia-like virus.

• Source

  The FDA got it partially right on e-cigs. Here’s what else needs to be done.

  (The Washington Post) – Responding to the worsening epidemic of e-cigarette use by kids of middle-school and high-school age, the Food and Drug Administration announced Thursday that it will ban, within 30 days, flavored e-liquids other than menthol and tobacco — but only when they’re packaged into cartridges to fit on popular devices such as those marketed by Juul.

• Source

  Scott Gottlieb: We must reduce access and appeal of flavored vapes to kids

  (CNBC) – Scott Gottlieb, former FDA commissioner and board member at Pfizer, joins CNBC to discuss a report from the New York Times released late on New Year’s Eve that indicates the White House is reportedly planning to ban most e-cigarette flavors but menthol and tobacco. 

• Source

  Access For 21st Century Cures: Updating Medicare’s Approach To Coverage And Payment

  (Health Affairs) – In recent years, considerable bipartisan Congressional action, leadership from both Democratic and Republican administrations, and broad-based multistakeholder collaborations have focused on improving the tools and regulatory processes at the Food and Drug Administration (FDA), other government agencies, and public-private collaborations to support more efficient and timely development of new medical technologies.

• Source

  Price Controls Would Stifle Biotech Innovation

  (The Wall Street Journal) – A House price-control bill would do the most damage to transformative and life-saving medications.

• Source

  Gottlieb: There’s a way to regulate e-cigs to protect children but not punish adult vapers

  (CNBC) – Former FDA commissioner Dr. Scott Gottlieb details what he thinks the administration should do about vaping.

• Source

  This is what the Trump administration should do on vaping

  (The Washington Post) – When regulations are contemplated to address an epidemic of teenagers using e-cigarettes, vaping advocates complain loudly. The restrictions will obstruct adult access to these products, they say, foreclosing the opportunity for smokers to use the devices to quit cigarettes.

• Source

  Gottlieb: Juul can’t keep their products out of the hands of kids

  (CNBC) – Pfizer board member and former FDA commissioner, Dr. Scott Gottlieb discusses e-cigarettes and how the administration is handling them. 

• Source

  Watch Obamacare architect and former FDA chief debate Elizabeth Warren’s Medicare for all plan

  (CNBC) – Elizabeth Warren’s $20.5 trillion plan to provide health care for all Americans is being attacked by Republicans and fellow Democrats. Dr. Zeke Emanuel, University of Pennsylvania vice provost and architect of Obamacare, and Dr. Scott Gottlieb, a Pfizer board member and former FDA commissioner, join CNBC to discuss.

• Source

  Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board of Directors

  (Yahoo Finance) – Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors.

• Source

  Why Scott Gottlieb is calling on the federal government to regulate marijuana

  (CNBC) – With news that the recent rise in lung illnesses has been linked to tainted marijuana liquid, former FDA Commissioner Scott Gottlieb’s asking the federal government to step in. In his most recent Wall Street Journal opinion piece, Dr. Gottlieb says it’s time to challenge state pot laws which he says promotes risky use of the controversial drug. 

• Source

  Pot Legalization Makes Vaping Deadly

  (Wall Street Journal) – Doctors have linked a tragic wave of lung injuries and deaths to the vaping of tainted marijuana concentrates. The episode reveals the dangers created by the federal government’s decadelong refusal to challenge state laws legalizing pot and promoting risky uses of its derivatives.

• Source

  Dr. Scott Gottlieb: Kids find cartridge-based vapes most accessible, appealing

  (CNBC) – Dr. Scott Gottlieb, a member on Pfizer’s board and former FDA commissioner, discusses the White House announcing a possible ban on e-cigarettes. 

• Source

  Here’s how illegal vapes might be making people sick

  (CNBC) -Dr. Scott Gottlieb, former FDA commissioner and currently a member of Pfizer’s board, discusses the five deaths that have now been linked to vaping. 

• Source

  E-cigarettes are not off the hook

  (Washington Post) – A mysterious lung illness that appears to be associated with vaping has swept across the country over the past few months, according to the Centers for Disease Control and Prevention.

• Source

  Don’t Give Up on Biosimilars—Congress Can Give Them a Boost

  (Wall Street Journal) – Drugs grown in live cells are hard to replicate. But policy changes can help accelerate the process.

• Source

  Gottlieb: Regulators needs to step up oversight on counterfit e-cigarettes

   (CNBC) – The Center for Disease Control reported 153 cases of severe lung disease linked to vaping in 16 states. In one case, an 18 year-old in Florida believes his lung collapsed after smoking an electronic cigarette. Investigators are looking into what’s causing these pulmonary illnesses. Former FDA Commissioner Dr. Scott Gottlieb, who also recently joined Pfizer’s board, joins CNBC to discuss.

• Source

  E-cigarette’s teen epidemic

  (CNBC) – Former FDA Commissioner Dr. Scott Gottlieb discusses what the government can do to lessen teen use but also make sure the product is available for adults who are trying to quit smoking.

• Source

  The CBD craze is getting out of hand. The FDA needs to act.

  (The Washington Post) – Cannabidiol — better known as CBD — is everywhere, from small specialty shops to large national retail chains. It can be found in foods, supplements, drugs, oils, creams, pet foods and more, and sellers purport that the compound treats everything from cancer to depression.

• Source

  Evaluating the Senate Finance Committee proposal to restructure Medicare Part D

  (AEI) – Senior citizens are facing increasing and often significant burdens from rising out-of-pocket costs on drugs that they need to improve their health while many observers worry about the long run stability of the Part D program.

• Source

  Scott Gottlieb on joining Pfizer’s board, drug prices, and ‘Medicare for All’

  (CNBC) – Former FDA Commissioner Scott Gottlieb was recently elected to the board of Pfizer. He joins “Squawk Box” to discuss the news as well as his thoughts on drug prices and “Medicare for All.”

• Source

  The FDA’s Challenge on E-Cigs

  (The Wall Street Journal) – Electronic cigarettes are less harmful than traditional cigarettes, but they aren’t safe. There’s evidence they can damage the lungs, and they’re also a path to nicotine addiction.

• Source

  Former FDA Chief Gottlieb on Juul: Don’t know how it proves public health benefit

  (CNBC) – Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, discusses Juul’s recent city-wide ban in San Francisco. Gottlieb tells Becky Quick that investors had to know Juul planned to sell to youths.

• Source

  The HELP Committee’s Fix For 180-Day Generic Marketing Exclusivity: Does It Solve The Problem?

  (Health Affairs) – The U.S. system for pricing drug innovation is forged on a careful balance between innovation and access. On the whole, American consumers consent to market-based pricing for novel drugs as a way to drive investment and reward scientific success. But no system is optimal. Too many patients struggle to obtain access to the resulting breakthroughs. Healthcare costs are straining public and private budgets.

• Source

  Good-bye to My Pal, FDA Commissioner Scott Gottlieb

  (The Cut) – Since his appointment in May of 2017, Gottlieb has earned wide bipartisan support as a public-health advocate (also unexpected, given his previous ties to the pharmaceutical industry), due in large part to his efforts to curb the opioid epidemic, which he told CNN last year was the “biggest crisis” facing the FDA.

• Source

  Here’s how the FDA might go about regulating CBD

  (CNBC) – FDA officials are hearing from executives at CBD companies, advocacy groups and researchers during an all-day meeting. Former FDA Commissioner Dr. Scott Gottlieb discusses the current landscape of CBD.

• Source

  Gottlieb sets a new standard for FDA commissioner

  (Modern Healthcare) – Dr. Scott Gottlieb has taken industry skeptics by surprise.

• Source

  Scott Gottlieb’s departure leaves the health of millions at stake

  (Washington Post) – ONE OF the Trump administration’s most competent, careful and effective senior officers will soon leave government. At stake is the health of millions of Americans.

• Source

  ‘Something very rare’: FDA’s Gottlieb aggressively tackled difficult issues

  (Politico) – FDA Commissioner Scott Gottlieb, who shocked Washington with news of his resignation on Tuesday, will leave the agency at the end of this month with a track record of activism and regulatory actions.

• Source

  Outgoing FDA chief Scott Gottlieb gets personal about leaving ‘the best job’ he’s ever had

  (CNBC) – In his nearly two years at the helm of the FDA, Gottlieb advanced sweeping initiatives like making cigarettes minimally or non-addictive and approving generic drugs faster. He published roughly 175 commissioner statements and gave countless media interviews, helping raise the FDA’s stature and influence.

• Source

  Silicon Valley just lost a friend with the exit of Gottlieb from the FDA

  (CNBC) – The departure of Scott Gottlieb from the U.S. Food and Drug Administration on Tuesday is a potential blow to Silicon Valley.

• Source

  We need to make sure new drug cures don’t widen income gap for the poor

  (CNBC) – Science offers the chance to cure debilitating and once-intractable disorders like hemophilia and sickle cell disease. But we need to make sure the ability to access these therapies, or the risk that someone can be locked out of them, doesn’t widen gaps between the rich and poor.

• Source

  The next FDA chief has big pro-consumer shoes to fill

  (The Hill) – During his Senate confirmation hearing in April 2017, Dr. Scott Gottlieb committed himself to “the gold standard of safety and efficacy.” Over the past two years as head of the Food and Drug Administration (FDA), Commissioner Gottlieb has made good on that promise, and his tenure has been a model for future FDA chiefs.

• Source

  The next FDA chief should follow Scott Gottlieb’s lead and end unnecessary animal testing

  (The Hill) – Just after announcing his resignation as FDA commissioner, Scott Gottlieb acknowledged this problem and pledged to reduce reliance on animals used for testing conducted by the agency’s scientists, as well as testing conducted by the industry.

• Source

  The king is dead, long live the king: Sharpless vows to continue Gottlieb era at FDA

  (FierceBiotech) – Scott Gottlieb’s relatively short two-year tenure as the FDA’s head has ended, and we have a new man at the helm: Ned Sharpless. However, he used his first official talk to ensure we all know he’s not looking to tear up Gottlieb’s legacy.

• Source

  Sen. Alexander Pays Tribute to FDA Commissioner Gottlieb

  (RELSCI) – Sen. Lamar Alexander, R-Tennessee, issued the following statement, which was published in the Congressional Record on April 9, paying tribute to Scott Gottlieb, commissioner of the Food and Drug Administration:

• Source

  FDA’s Gottlieb heads back to AEI to tackle drug prices

  (The Washington Post) – Scott Gottlieb, who will step down as commissioner of the Food and Drug Administration on Friday, plans to return to the American Enterprise Institute to focus on drug prices — a hotly debated area that has been peripheral to his current job, he said in an interview.

• Source

  Rx Drug Policy At The FDA: Looking Back At Gottlieb And Ahead To Sharpless

  (Health Affairs) – This week is expected to be Dr. Scott Gottlieb’s last as Commissioner of the U.S. Food and Drug Administration (FDA). During his nearly two years in the position, Commissioner Gottlieb has confronted a range of public health challenges, including the opioid epidemic, an increase in teen nicotine abuse, and natural disasters.

• Source

  FDA Needs To Change How It Regulates Novel Technologies

  (Forbes) – I spoke before a meeting of the International Society for Stem Cell Research in Berkeley, Calif., this week, addressing the need for the Food and Drug Administration to adapt how it approaches pre-market regulation in order to properly address very novel areas of technology like gene editing and cell and gene therapy.

• Source

  Applying to Zika the Forgotten Lessons of Ebola

  Panic turns to complacency when the threat subsides. That’s no way to handle potential pandemics.

• Source

  The Coming Government Takeover of Drug Pricing

  (The Wall Street Journal) – ObamaCare provides the tools for a unilateral move against the industry the left loves to demonize.

• Source

  Private Health Plan Rates Are Set To Spike Next Year

  By Dr. Scott Gottlieb

  (Forbes) – It isn’t just Obamacare premiums that are set to spike next year.

• Source

  Dr. Scott Gottlieb says Hillary Clinton’s plan to lower drug costs is ‘misdirected’

  (Becker’s Hospital Review) – What [Ms. Clinton] fails to comprehend is that the high drug prices she decries aren’t the result of market forces gone wild. Rather, they are the result of bad regulation that has created market failures and shortages

• Source

  Patients face dwindling choices

  (Republican American) – The number of distinct health-plan choices people have at work, or even on the Obamacare exchanges, has shrunk under the Obama presidency.

• Source

  Closing the Planned Parenthood Loophole

  By Scott Gottlieb
  (The Wall Street Journal) – Whatever your stance on abortion, it’s clear the laws governing fetal tissue don’t work—and should be fixed.

• Source

  A Practical Plan For Replacing Obamacare

  The Walker Plan reverts regulation of insurance back to the states, enabling a much wider range of networks, coverage, and plan design. Consumers will get a real choice again.

• Source

  How The Feds Discourage Prescription Drug Competition

  There’s a growing refrain among those who pay for healthcare services that they want new products to deliver more value… Drugs that deliver more bang for the buck.

• Source

  The Clintonian Roots of Obamacare

  An article by Scott Gottlieb tracing the similarities between the Affordable Care Act and the various healthcare proposals advanced by Secretary Hillary Clinton over the past two decades of her career.

• Source

  Drug pricing drives debates at BIO convention

  PHILADELPHIA: Philadelphia this week welcomed 15,000 healthcare professionals from more than 70 countries to the annual BiO International Convention, the largest global event for the biotechnology industry.

  Scott Gottlieb, resident fellow of think tank American Enterprise Institute, offered a timeline on scientific discovery. While it took the world 300 years to grasp how germs cause disease, now the “breakneck speed” of discoveries is measured in months. The biggest impediment to innovation, in Gottlieb’s mind, is the policy obstacles that prevent experimentation with how drugs are priced and contracted.

• Source

  The Quickening Pace Of Medical Progress And Its Discontents

  An article written by Scott Gottlieb, MD featured in Forbes on the “creative destruction is an increasingly prominent feature of modern medical practice.” 

• Source

  How Not to Bungle an ObamaCare Opening

  by Scott Gottlieb & Tevi Troy
  (WSJ) – Republican congressional leaders were wise to propose an alternative to the Affordable Care Act this week, as the Supreme Court may strike down a key provision of the law after hearing King v. Burwell next month. The case involves subsidies to individuals who purchase health insurance on federal exchanges. The plaintiffs—four individuals who don't want to be forced to buy ObamaCare—argue that under the explicit terms of the ACA, subsidies enabling that purchase can only be distributed in exchanges "established by the State." The court is expected to rule by the end of June, and the plaintiffs have a good chance of convincing a majority that the subsidies are unlawful.

• Source

  Scott Gottlieb on How Obamacare’s Bad Math Will Force Insurers To Downgrade Earnings

  Some of the biggest health insurers are baking faulty math into their earnings forecasts by factoring in payments from Uncle Sam that may never materialize.

  Two events this week could force a reckoning between their wishful arithmetic and common auditing standards – forcing insures to downgrade their earnings.

  At issue are risk-sharing arrangements contained in Obamacare that are meant to help offset losses insures might take as the program gets started. Collectively, these programs have become known as “the three Rs” because of their three elements.

• Source

  How Obama’s FDA Keeps Generic Drugs Off the Market

  (The Wall Street Journal) – A flurry of new regulations is raising production costs and reducing competition for branded drugs.

• Source

  ‘I’m An Astronaut. This Is What It’s Like To Walk In Space’

  (Newsweek) – Over the past few weeks a common joke I hear from family and friends is: “Hey Mike, I bet you wish you were in space now!”

• Scott Gottlieb MD Full Bio

• Scott Gottlieb Interactive One Pager